Development of photocrosslinked sialic acid containing polymers for use in Aβ toxicity attenuation

Biomaterials

Volumn 29, Issue 24-25, 2008, Pages 3408-3414

  Cowan, Christopher B ^a   Coté, Gerard L ^b   Good, Theresa A ^a  

^a University of Marylandw Baltimore County   (United States)

^b Texas A and M University   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Multivalent; Oligosaccharide; Photopolymerization; Sialic acid

Indexed keywords

ALZHEIMER'S DISEASE; BETA-AMYLOID; SIALIC ACID;

CROSSLINKING; OLIGOSACCHARIDES; PHOTOPOLYMERIZATION; TOXICITY;

ORGANIC ACIDS;

AMYLOID BETA PROTEIN; OLIGOSACCHARIDE; POLYMER; SIALIC ACID;

ARTICLE; CELL CULTURE; CELL SURFACE; CELL VIABILITY; CROSS LINKING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CROSS-LINKING REAGENTS; MOLECULAR STRUCTURE; N-ACETYLNEURAMINIC ACID; OLIGOSACCHARIDES; POLYMERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 46549089088     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.05.001     Document Type: Article

References (57)

1. Patel D., Henry J., and Good T. Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochim Biophys Acta 1760 12 (2006) 1802-1809
2. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88 9 (1998) 1337-1342
3. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100 18 (2003) 10417-10422
4. Hensley K., Butterfield D.A., Mattson M., Aksenova M., Harris M., Wu J.F., et al. A model for beta-amyloid aggregation and neurotoxicity based on the free radical generating capacity of the peptide: implications of "molecular shrapnel" for Alzheimer's disease. Proc West Pharmacol Soc 38 (1995) 113-120
5. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., et al. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem J 348 Pt 1 (2000) 137-144
6. Doig A.J., Hughes E., Burke R.M., Su T.J., Heenan R.K., and Lu J. Inhibition of toxicity and protofibril formation in the amyloid-beta peptide beta(25-35) using N-methylated derivatives. Biochem Soc Trans 30 4 (2002) 537-542
7. Choo-Smith L.P., and Surewicz W.K. The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett 402 2-3 (1997) 95-98
8. Arispe N., Rojas E., and Pollard H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 90 2 (1993) 567-571
9. Kakio A., Yano Y., Takai D., Kuroda Y., Matsumoto O., Kozutsumi Y., et al. Interaction between amyloid beta-protein aggregates and membranes. J Pept Sci 10 10 (2004) 612-621
10. Mott R.T., and Hulette C.M. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 15 4 (2005) 755-765 ix
11. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 100 11 (2003) 6370-6375
12. Wang S.S., Becerra-Arteaga A., and Good T.A. Development of a novel diffusion-based method to estimate the size of the aggregated abeta species responsible for neurotoxicity. Biotechnol Bioeng 80 1 (2002) 50-59
13. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279 45 (2004) 46363-46366
14. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277 35 (2002) 32046-32053
15. Whitson J.S., Mims M.P., Strittmatter W.J., Yamaki T., Morrisett J.D., and Appel S.H. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun 199 1 (1994) 163-170
16. Sokolov Y., Kozak J.A., Kayed R., Chanturiya A., Glabe C., and Hall J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128 6 (2006) 637-647
17. Kilsdonk E.P., Yancey P.G., Stoudt G.W., Bangerter F.W., Johnson W.J., Phillips M.C., et al. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 270 29 (1995) 17250-17256
18. Arispe N., Pollard H.B., and Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A 90 22 (1993) 10573-10577
19. Diaz J.C., Linnehan J., Pollard H., and Arispe N. Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease Abeta ion channel and cytotoxicity. Biol Res 39 3 (2006) 447-460
20. Butterfield D.A., Griffin S., Munch G., and Pasinetti G.M. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 4 3 (2002) 193-201
21. Varadarajan S., Yatin S., Aksenova M., and Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130 2-3 (2000) 184-208
22. Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., and Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch Biochem Biophys 388 2 (2001) 225-230
23. Ariga T., and Yu R.K. GM1 inhibits amyloid beta-protein-induced cytokine release. Neurochem Res 24 2 (1999) 219-226
24. Matsuzaki K., and Horikiri C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38 13 (1999) 4137-4142
25. Wakabayashi M., Okada T., Kozutsumi Y., and Matsuzaki K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem Biophys Res Commun 328 4 (2005) 1019-1023
26. Yanagisawa K., Odaka A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1 10 (1995) 1062-1066
27. Zha Q., Ruan Y., Hartmann T., Beyreuther K., and Zhang D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 9 10 (2004) 946-952
28. Ariga T., Kiso M., Hasegawa A., and Miyatake T. Gangliosides inhibit the release of interleukin-1beta in amyloid beta-protein-treated human monocytic cells. J Mol Neurosci 17 3 (2001) 371-377
29. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41 23 (2002) 7385-7390
30. Kakio A., Nishimoto S.I., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276 27 (2001) 24985-24990
31. Baier Leach J., Bivens K.A., Patrick Jr. C.W., and Schmidt C.E. Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol Bioeng 82 5 (2003) 578-589
32. Bhavanandan V.P., and Sheykhnazari M. Adaptation of the periodate-resorcinol method for determination of sialic acids to a microassay using microtiter plate reader. Anal Biochem 213 2 (1993) 438-440
33. van Engeland M., Ramaekers C.S., Schutte B., and Reutelingsperger C.P.M. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24 (1996) 131-139
34. Reuter J.D., Myc A., Hayes M.M., Gan Z., Roy R., Qin D., et al. Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Bioconjug Chem 10 2 (1999) 271-278
35. Landers J.J., Cao Z., Lee I., Piehler L.T., Myc P.P., Myc A., et al. Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. J Infect Dis 186 9 (2002) 1222-1230
36. Patel D.A., Henry J.E., and Good T.A. Attenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment. Brain Res 1161 (2007) 95-105
37. Kim I.S., Jeong Y.I., Kim D.H., Lee Y.H., and Kim S.H. Albumin release from biodegradable hydrogels composed of dextran and poly(ethylene glycol) macromer. Arch Pharm Res 24 1 (2001) 69-73
38. Trudel J., and Massia S.P. Assessment of the cytotoxicity of photocrosslinked dextran and hyaluronan-based hydrogels to vascular smooth muscle cells. Biomaterials 23 16 (2002) 3299-3307
39. Chen F.M., Zhao Y.M., Zhang R., Jin T., Sun H.H., Wu Z.F., et al. Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins. J Controlled Release 121 1-2 (2007) 81-90
40. Flores-Ramirez N., Elizalde-Pena E.A., Vasquez-Garcia S.R., Gonzalez-Hernandez J., Martinez-Ruvalcaba A., Sanchez I.C., et al. Characterization and degradation of functionalized chitosan with glycidyl methacrylate. J Biomater Sci Polym Ed 16 4 (2005) 473-488
41. Leach J.B., Bivens K.A., Collins C.N., and Schmidt C.E. Development of photocrosslinkable hyaluronic acid-polyethylene glycol-peptide composite hydrogels for soft tissue engineering. J Biomed Mater Res A 70 1 (2004) 74-82
42. Reis A.V., Cavalcanti O.A., Rubira A.F., and Muniz E.C. Synthesis and characterization of hydrogels formed from a glycidyl methacrylate derivative of galactomannan. Int J Pharm 267 1-2 (2003) 13-25
43. Laidler P., Litynska A., Hoja-Lukowicz D., Labedz M., Przybylo M., Ciolczyk-Wierzbicka D., et al. Characterization of glycosylation and adherent properties of melanoma cell lines. Cancer Immunol Immunother 55 1 (2006) 112-118
44. van Rossenberg S.M., Sliedregt L.A., Autar R., Piperi C., Van Der Merwe A.P., van Berkel T.J., et al. A structure-function study of ligand recognition by CD22beta. J Biol Chem 276 16 (2001) 12967-12973
45. Nakata D., and Troy II F.A. Degree of polymerization (DP) of polysialic acid (polySia) on neural cell adhesion molecules (N-CAMS): development and application of a new strategy to accurately determine the DP of polySia chains on N-CAMS. J Biol Chem 280 46 (2005) 38305-38316
46. Chang W.W., Yu C.Y., Lin T.W., Wang P.H., and Tsai Y.C. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem Biophys Res Commun 341 2 (2006) 614-619
47. Aubert M., Panicot L., Crotte C., Gibier P., Lombardo D., Sadoulet M.O., et al. Restoration of alpha(1,2) fucosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells. Cancer Res 60 5 (2000) 1449-1456
48. Huskens J. Multivalent interactions at interfaces. Curr Opin Chem Biol 10 6 (2006) 537-543
49. Kumar P.V., Asthana A., Dutta T., and Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 14 8 (2006) 546-556
50. Lees W.J., Spaltenstein A., Kingery-Wood J.E., and Whitesides G.M. Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems. J Med Chem 37 20 (1994) 3419-3433
51. Polizzotti B.D., and Kiick K.L. Effects of polymer structure on the inhibition of cholera toxin by linear polypeptide-based glycopolymers. Biomacromolecules 7 2 (2006) 483-490
52. Prieto M.J., Bacigalupe D., Pardini O., Amalvy J.I., Venturini C., Morilla M.J., et al. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. Int J Pharm 326 1-2 (2006) 160-168
53. Woller E.K., and Cloninger M.J. The lectin-binding properties of six generations of mannose-functionalized dendrimers. Org Lett 4 1 (2002) 7-10
54. Cairo C.W., Strzelec A., Murphy R.M., and Kiessling L.L. Affinity-based inhibition of beta-amyloid toxicity. Biochemistry 41 27 (2002) 8620-8629
55. Pallitto M.M., and Murphy R.M. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys J 81 3 (2001) 1805-1822
56. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., et al. Peripheral treatment with Enoxaparin, a low molecular weight heparin, reduces plaques and β-Amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24 17 (2004) 4181-4186
57. Vasilevko V., Xu F., Previti M.L., Van Nostrand W.E., and Cribbs D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci 27 (2007) 13376-13383